Mivacron (Mivacurium Chloride)

Mivacurium chloride, the active ingredient in Mivacron, is a non‑depolarizing neuromuscular blocking agent presented as an injectable solution for intravenous use. It facilitates endotracheal intubation, provides skeletal muscle relaxation during surgery, and assists ventilation in intensive‑care settings.

GNH USA supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, with distribution across EU and other regulated markets. The company ensures product quality through stringent quality‑assurance processes and compliance with global regulatory standards.

Mivacron, a non‑depolarizing neuromuscular blocker, is used in clinical situations that require rapid skeletal muscle relaxation.

- Facilitation of endotracheal intubation: provides short‑acting muscle relaxation to allow safe airway placement. - Skeletal muscle relaxation during surgery: enables controlled paralysis for optimal surgical conditions. - Assistance with ventilation in intensive care: supports mechanical ventilation by reducing patient effort.

Mivacron may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Flushing: transient reddening of the skin due to histamine release. - Histamine‑related hypotension: mild drop in blood pressure. - Tachycardia: temporary increase in heart rate. - Bronchospasm: narrowing of the airways, especially in susceptible individuals. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Prolonged paralysis: extended muscle weakness beyond expected duration. - Malignant hyperthermia trigger: rare hypermetabolic crisis in susceptible patients. - Cardiac arrest: life‑threatening cessation of heart activity. - Severe bronchospasm: intense airway constriction leading to respiratory distress.

When using Mivacron, clinicians should observe several safety measures to minimize risk.

- Neuromuscular monitoring: assess depth of blockade continuously. - Hemodynamic observation: watch for hypotension and tachycardia. - Hypersensitivity screening: avoid in patients with known allergy to mivacurium or related compounds. - Hepatic/renal impairment: use caution and consider dose adjustment in reduced‑function patients. - Elderly patients: initiate with lower doses and titrate carefully. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with other agents that influence neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid): - Other neuromuscular blocking agents: additive paralysis. - Aminoglycoside antibiotics (e.g., gentamicin): potentiate blockade. - Magnesium sulfate: enhances muscle relaxation. - Potent cholinesterase inhibitors (e.g., neostigmine in high doses): may reduce effectiveness. - Volatile anesthetics at high concentrations: increase risk of hypotension.

Moderate Interactions (Monitor Closely): - Calcium channel blockers: may augment hypotensive effect. - Beta‑blockers: can mask tachycardia response. - Diuretics: potential electrolyte shifts affecting neuromuscular function. - Opioids: synergistic respiratory depression. - Antihistamines: may alter histamine‑mediated side‑effects.